Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aventis Taxotere

Executive Summary

Supplemental indication for docetaxel for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior platinum based chemotherapy approved Dec. 23. Labeling points out that "only one of the two [clinical] trials [for the NSCLC indication] showed a clear effect on survival," but notes that one-year survival rates favored Taxotere in both trials. Labeling also warns that the 100 mg/m2 dose was unacceptably toxic in trials for the NSCLC indication. Docetaxel is already approved for second-line treatment of locally advanced or metastatic breast cancer. The new indication was recommended for approval Dec. 13 ("The Pink Sheet" Dec. 20, 1999, p. 8)
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS035360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel